SK Biopharmaceuticals Co., Ltd. (KRX:326030)

South Korea flag South Korea · Delayed Price · Currency is KRW
100,600
+400 (0.40%)
At close: Aug 14, 2025, 3:30 PM KST
1.82%
Market Cap 7.85T
Revenue (ttm) 578.00B
Net Income (ttm) 251.21B
Shares Out 78.31M
EPS (ttm) 3,207.77
PE Ratio 31.24
Forward PE 39.35
Dividend n/a
Ex-Dividend Date n/a
Volume 228,140
Average Volume 376,759
Open 100,500
Previous Close 100,200
Day's Range 99,800 - 102,100
52-Week Range 86,900 - 130,000
Beta 0.87
RSI 50.87
Earnings Date Aug 8, 2025

About SK Biopharmaceuticals

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication, for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials for treatment of rare neurological disease; SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy; SKL20540, w... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1993
Employees 241
Stock Exchange Korea Stock Exchange
Ticker Symbol 326030
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.